Literature DB >> 36154359

Functional mgrA Influences Genetic Changes within a Staphylococcus aureus Cell Population over Time.

James Lee1,2,3, Miguel Carda-Diéguez4, Miglė Žiemytė4, Sarah Vreugde5, Clare Cooksley5, Heidi A Crosby6, Alexander R Horswill6, Alex Mira4, Peter S Zilm7, Stephen P Kidd1,2,3.   

Abstract

Prolonged survival in the host-bacteria microenvironment drives the selection of alternative cell types in Staphylococcus aureus, permitting quasi-dormant sub-populations to develop. These facilitate antibiotic tolerance, long-term growth, and relapse of infection. Small Colony Variants (SCV) are an important cell type associated with persistent infection but are difficult to study in vitro due to the instability of the phenotype and reversion to the normal cell type. We have previously reported that under conditions of growth in continuous culture over a prolonged culture time, SCVs dominated a heterogenous population of cell types and these SCVs harbored a mutation in the DNA binding domain of the gene for the transcription factor, mgrA. To investigate this specific cell type further, S. aureus WCH-SK2-ΔmgrA itself was assessed with continuous culture. Compared to the wild type, the mgrA mutant strain required fewer generations to select for SCVs. There was an increased rate of mutagenesis within the ΔmgrA strain compared to the wild type, which we postulate is the mechanism explaining the increased emergence of SCV selection. The mgrA derived SCVs had impeded metabolism, altered MIC to specific antibiotics and an increased biofilm formation compared to non-SCV strain. Whole genomic sequencing detected single nucleotide polymorphisms (SNP) in phosphoglucosamine mutase glmM and tyrosine recombinase xerC. In addition, several genomic rearrangements were detected which affected genes involved in important functions such as antibiotic and toxic metal resistance and pathogenicity. Thus, we propose a direct link between mgrA and the SCV phenotype. IMPORTANCE Within a bacterial population, a stochastically generated heterogeneity of phenotypes allows continual survival against current and future stressors. The generation of a sub-population of quasi-dormant Small Colony Variants (SCV) in Staphylococcus aureus is such a mechanism, allowing for persistent or relapse of infection despite initial intervention seemingly clearing the infection. The use of continuous culture under clinically relevant conditions has allowed us to introduce time to the growth system and selects SCV within the population. This study provides valuable insights into the generation of SCV which are not addressed in standard laboratory generated models and reveals new pathways for understanding persistent S. aureus infection which can potentially be targeted in future treatments of persistent S. aureus infection.

Entities:  

Keywords:  Small Colony Variants; Staphylococcus aureus; persistence

Mesh:

Substances:

Year:  2022        PMID: 36154359      PMCID: PMC9578419          DOI: 10.1128/jb.00138-22

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.476


  58 in total

Review 1.  Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections.

Authors:  Richard A Proctor; Christof von Eiff; Barbara C Kahl; Karsten Becker; Peter McNamara; Mathias Herrmann; Georg Peters
Journal:  Nat Rev Microbiol       Date:  2006-04       Impact factor: 60.633

2.  Prolonged growth of a clinical Staphylococcus aureus strain selects for a stable small-colony-variant cell type.

Authors:  Long M G Bui; Peter Hoffmann; John D Turnidge; Peter S Zilm; Stephen P Kidd
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

Review 3.  Microbial bet-hedging: the power of being different.

Authors:  Ard Jan Grimbergen; Jeroen Siebring; Ana Solopova; Oscar P Kuipers
Journal:  Curr Opin Microbiol       Date:  2015-05-27       Impact factor: 7.934

Review 4.  Adaptation of Staphylococcus aureus to the cystic fibrosis lung.

Authors:  Christiane Goerke; Christiane Wolz
Journal:  Int J Med Microbiol       Date:  2010-09-16       Impact factor: 3.473

5.  MgrA represses biofilm formation in Staphylococcus aureus.

Authors:  María Pilar Trotonda; Sandeep Tamber; Guido Memmi; Ambrose L Cheung
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

6.  Rat/MgrA, a regulator of autolysis, is a regulator of virulence genes in Staphylococcus aureus.

Authors:  Susham Ingavale; Willem van Wamel; Thanh T Luong; Chia Y Lee; Ambrose L Cheung
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

7.  Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection.

Authors:  Lorena Tuchscherr; Eva Medina; Muzaffar Hussain; Wolfgang Völker; Vanessa Heitmann; Silke Niemann; Dirk Holzinger; Johannes Roth; Richard A Proctor; Karsten Becker; Georg Peters; Bettina Löffler
Journal:  EMBO Mol Med       Date:  2011-01-26       Impact factor: 12.137

8.  Staphylococcus aureus adapts to oxidative stress by producing H2O2-resistant small-colony variants via the SOS response.

Authors:  Kimberley L Painter; Elizabeth Strange; Julian Parkhill; Kathleen B Bamford; Darius Armstrong-James; Andrew M Edwards
Journal:  Infect Immun       Date:  2015-02-17       Impact factor: 3.441

9.  Cyclic di-adenosine monophosphate (c-di-AMP) is required for osmotic regulation in Staphylococcus aureus but dispensable for viability in anaerobic conditions.

Authors:  Merve S Zeden; Christopher F Schuster; Lisa Bowman; Qiyun Zhong; Huw D Williams; Angelika Gründling
Journal:  J Biol Chem       Date:  2018-01-11       Impact factor: 5.157

10.  The Energy-Coupling Factor Transporter Module EcfAA'T, a Novel Candidate for the Genetic Basis of Fatty Acid-Auxotrophic Small-Colony Variants of Staphylococcus aureus.

Authors:  Nina Schleimer; Ursula Kaspar; Mike Drescher; Jochen Seggewiß; Christof von Eiff; Richard A Proctor; Georg Peters; André Kriegeskorte; Karsten Becker
Journal:  Front Microbiol       Date:  2018-08-14       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.